The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Issues
Latest issue
Regular issues
Supplements
PCR Trials
All issues
Articles
Regular articles
Ahead of print
All articles
Topics
Coronary interventions
STEMI
NSTEMI
Stable CAD
Stents and scaffolds
Left main and multivessel disease
Bifurcation lesions
CTO
Other coronary interventions
Interventions for valvular disease
TAVI
Mitral valve replacement and repair
Tricuspid / Pulmonary valve
Other valvular and structural interventions
Interventions for heart failure
Acute heart failure
Chronic heart failure
Peripheral interventions
Below the knee
Abdominal aortic aneurysm
Iliac / Femoral / Popliteal
Other peripheral interventions
Interventions for hypertension
Renal artery angioplasty
Renal denervation
Other hypertension
Interventions for stroke
Carotid stenting
LAA closure
Ischaemic stroke
Other stroke interventions
News
Services
Subscribe
Advertise
Reprint-Eprint
Join our mailing list
About
Overview
Editorial board
Rights & permissions
Contact us
Author centre
Cécile Dorange
Showing 1-12 of 12 articles
The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled
Abizaid A,
Costa Jr J,
Bartorelli A,
Whitbourn R,
van Geuns R,
Chevalier B,
Patel T,
Seth A,
Stuteville M,
Dorange C,
Cheong W-F,
Sudhir K,
Serruys P
April 20, 2015 | 10.4244/EIJV10I12A243
Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial
Bourantas C,
Farooq V,
Zhang Y-J,
Muramatsu T,
Gogas B,
Thuesen L,
McClean D,
Chevalier B,
Windecker S,
Koolen J,
Ormiston J,
Whitbourn R,
Dorange C,
Rapoza R,
Onuma Y,
Garcia-Garcia H,
Serruys P
March 20, 2015 | 10.4244/EIJY14M04_11
Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)
Simsek C,
Magro M,
Onuma Y,
Boersma E,
Smits P,
Dorange C,
Veldhof S,
Regar E,
Serruys P,
van Geuns R
June 20, 2014 | 10.4244/EIJV10I2A38
Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months
Serruys P,
Onuma Y,
Garcia-Garcia H,
Muramatsu T,
van Geuns R,
De Bruyne B,
Dudek D,
Thuesen L,
Smits P,
Chevalier B,
McClean D,
Koolen J,
Windecker S,
Whitbourn R,
Meredith I,
Dorange C,
Veldhof S,
Hebert K,
Rapoza R,
Ormiston J
March 20, 2014 | 10.4244/EIJV9I11A217
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials
Gogas B,
Bourantas C,
Garcia-Garcia H,
Onuma Y,
Muramatsu T,
Farooq V,
Diletti R,
van Geuns R,
De Bruyne B,
Chevalier B,
Thuesen L,
Smits P,
Dudek D,
Koolen J,
Windecker S,
Whitbourn R,
McClean D,
Dorange C,
Miquel-Hebert K,
Veldhof S,
Rapoza R,
Ormiston J,
Serruys P
October 25, 2013 | 10.4244/EIJV9I6A115
Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study
Gomez-Lara J,
Diletti R,
Brugaletta S,
Onuma Y,
Farooq V,
Thuesen L,
McClean D,
Koolen J,
Ormiston J,
Windecker S,
Whitbourn R,
Dudek D,
Dorange C,
Veldhof S,
Rapoza R,
Regar E,
Garcia-Garcia H,
Serruys P
June 27, 2012
Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study
Brugaletta S,
Garcia-Garcia H,
Diletti R,
Gomez-Lara J,
Garg S,
Onuma Y,
Shin E,
van Geuns R,
De Bruyne B,
Dudek D,
Thuesen L,
Chevalier B,
McClean D,
Windecker S,
Whitbourn R,
Dorange C,
Veldhof S,
Rapoza R,
Sudhir K,
Bruining N,
Ormiston J,
Serruys P
April 20, 2011
Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial
Khattab A,
Richardt G,
Verin V,
Kelbæk H,
Macaya C,
Berland J,
Miquel-Hebert K,
Dorange C,
Serruys P
March 20, 2008
One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study
Ruygrok P,
Desaga M,
Van den Branden B,
Rasmussen K,
Suryapranata H,
Dorange C,
Veldhof S,
Serruys P
November 20, 2007
Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial)
Beijk M,
Neumann F,
Wiemer M,
Grube E,
Haase J,
Thuesen L,
Hamm C,
Veldhof S,
Dorange C,
Serruys P,
Piek J
August 20, 2007
Prospective non-randomized multi-center evaluation of the non-polymer based ACHIEVE™ Paclitaxel Eluting Coronary Stent System in treatment of lesions with high risk of revascularization due to restenosis: the DELIVER II study
Grube E,
Gershlick A,
Bartorelli A,
Buellesfeld L,
Blanchard D,
Macaya C,
Buettner H,
Lim V,
Boone E,
Dorange C,
Marco J
February 20, 2006
One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings<br />(The SPIRIT FIRST Trial)
Tsuchida K,
Piek J,
Neumann F,
van der Giessen WJ,
Wiemer M,
Zeiher A,
Grube E,
Haase J,
Thuesen L,
Hamm C,
Veldhof S,
Dorange C,
Serruys P
November 20, 2005
1
Latest news
AHEAD OF PRINT
Delayed hospitalisation in the MITRA-FR trial
FREE ARTICLE - Guillaume Leurent et al
May 25, 2022
EUROPCR LATE BREAKING
EuroPCR 2022 Late-breaking publications: watch the interviews with the authors!
May 23, 2022
NEW ISSUE
TAVI vs SAVR for bicuspid anatomies; PVR and TAVI; LAA thrombus trapping; crush techniques for bifurcation PCIs; stent elongation in POT and more
May 18, 2022
AHEAD OF PRINT
Complete cerebral protection during TAVI
FREE ARTICLE - Dariusz Jagielak et al
May 24, 2022
AHEAD OF PRINT
Outcomes of PCI for stent thrombosis
FREE ARTICLE - Mohamed O. Mohamed et al
May 24, 2022
EUROPCR LATE BREAKING
Changes in voice patterns for monitoring heart failure deterioration
FREE ARTICLE - Chaim Lotan et al
May 24, 2022
EUROPCR LATE BREAKING
SavvyWire in TAVI
FREE ARTICLE - Josep Rodés-Cabau et al
May 24, 2022
Coronary
Valvular disease
Heart failure
Peripheral
Hypertension
Stroke